Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
NEREUS (tradipitant) is an oral small-molecule capsule approved in December 2025 by the FDA as a new drug application. The mechanism of action and specific indications have not been disclosed in available data, limiting detail on therapeutic area and patient population.
Early commercial launch phase offers opportunity to build brand awareness and establish market position with limited current spending data; launch team likely expanding across sales, marketing, and medical affairs.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Worked on NEREUS at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moNEREUS launch at Vanda Pharmaceuticals offers entry or advancement opportunity in a newly commercialized product with minimal competitive pressure and a decade-long patent runway. Career trajectory benefits from early-stage growth phase with established safety profile and no REMS complexity.